Factors that affect the false negative rate of sentinel lymph node mapping with methylene blue dye alone in breast cancer
- PMID: 31507208
- PMCID: PMC6833398
- DOI: 10.1177/0300060519827413
Factors that affect the false negative rate of sentinel lymph node mapping with methylene blue dye alone in breast cancer
Abstract
Objective: This study aimed to investigate the clinicopathological factors of the false negative rate (FNR) and accuracy of sentinel lymph node biopsy (SLNB) mapping with 1% methylene blue dye (MBD) alone, and to examine how to reduce the FNR in patients with breast cancer.
Methods: A total of 365 patients with invasive breast carcinoma who received axillary lymph node dissection after SLNB were retrospectively analyzed. SLNB was performed with 2 to 5 mL of 1% MBD. We studied the clinicopathological factors that could affect the FNR of SLNB.
Results: The identification rate of sentinel lymph nodes (SLNs) was 98.3% (359/365) and the FNR of SLNB was 10.4% (16/154). Multivariate analysis showed that the number of dissected SLNs and metastatic lymph nodes were independent predictive factors for the FNR of SLNB. The FNR in patients with 1, 2, 3, and ≥4 SLNs was 23.53%, 15.79%, 3.85%, and 1.79%, respectively.
Conclusions: SLNB mapping with MBD alone in patients with breast cancer can produce favorable identification rates. The FNR of SLNB decreases as the number of SLNs rises. Because of side effects of searching for additional SLNs and the FNR, removal of three or four SLNs may be appropriate.
Keywords: Breast neoplasm; axillary lymph node dissection; false negative rate (FNR); metastasis; methylene blue; sentinel lymph node biopsy (SLNB).
Similar articles
-
Optimization of sentinel lymph node identification techniques in the Indian setting: A randomized clinical trial.Indian J Cancer. 2019 Apr-Jun;56(2):114-118. doi: 10.4103/ijc.IJC_163_18. Indian J Cancer. 2019. PMID: 31062728 Clinical Trial.
-
[Comparison of sentinel lymph node detection by methylene blue and carbon nanoparticle suspension injection in early breast cancer].Zhonghua Zhong Liu Za Zhi. 2011 Mar;33(3):226-8. Zhonghua Zhong Liu Za Zhi. 2011. PMID: 21575525 Chinese.
-
The role of sentinel lymph node biopsy with blue dye alone in breast cancer patients with excisional biopsy.Acta Chir Belg. 2005 May-Jun;105(3):291-6. doi: 10.1080/00015458.2005.11679719. Acta Chir Belg. 2005. PMID: 16018523 Clinical Trial.
-
Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients.J Surg Oncol. 2004 Mar;85(3):102-11. doi: 10.1002/jso.20022. J Surg Oncol. 2004. PMID: 14991881 Review.
-
Clinical practice guidelines for the use of axillary sentinel lymph node biopsy in carcinoma of the breast: current update.Breast J. 2004 Mar-Apr;10(2):85-8. doi: 10.1111/j.1075-122x.2004.21439.x. Breast J. 2004. PMID: 15009032 Review.
Cited by
-
Predictive value of methylene blue combined with indocyanine green in sentinel lymph node metastasis in breast cancer: a prospective pilot cohort study.Front Oncol. 2024 Oct 9;14:1433907. doi: 10.3389/fonc.2024.1433907. eCollection 2024. Front Oncol. 2024. PMID: 39445056 Free PMC article.
-
Applying Explainable Machine Learning Models for Detection of Breast Cancer Lymph Node Metastasis in Patients Eligible for Neoadjuvant Treatment.Cancers (Basel). 2023 Jan 19;15(3):634. doi: 10.3390/cancers15030634. Cancers (Basel). 2023. PMID: 36765592 Free PMC article.
-
Associations between the Levels of Estradiol-, Progesterone-, and Testosterone-Sensitive MiRNAs and Main Clinicopathologic Features of Breast Cancer.J Pers Med. 2021 Dec 21;12(1):4. doi: 10.3390/jpm12010004. J Pers Med. 2021. PMID: 35055320 Free PMC article.
-
Vitamin D and myopia: a review.Int Ophthalmol. 2024 Feb 18;44(1):95. doi: 10.1007/s10792-024-03009-9. Int Ophthalmol. 2024. PMID: 38368573 Review.
-
Quantitative and Semi-quantitative Methods for Assessing the Degree of Methylene Blue Staining in Sentinel Lymph Nodes in Dogs.Front Vet Sci. 2021 Oct 21;8:758295. doi: 10.3389/fvets.2021.758295. eCollection 2021. Front Vet Sci. 2021. PMID: 34746290 Free PMC article.
References
-
- Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 2010; 252: 426–433. - PMC - PubMed
-
- Andersson Y, de Boniface J, Jönsson PE, et al. Axillary recurrence rate 5 years after negative sentinel node biopsy for breast cancer. Br J Surg 2012; 99: 226–231. - PubMed
-
- Land SR, Kopec JA, Julian TB, et al. Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axilliary dissection: National surgical adjuvant breast and bowel project phase III protocol B-32. J Clin Oncol 2010; 28: 3929–3936. - PMC - PubMed
-
- Pepels MJ, Vestjens JH, de Boer M. Safety of avoiding routine use of axillary dissection in early stage breast cancer: a systematic review. Breast Cancer Res Treat 2011; 125: 301–313. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical